Cuu Long Pharmaceutical JSC (HOSE:DCL)
Vietnam
· Delayed Price · Currency is VND 20,400
-200 (-0.97%)
At close: Apr 22, 2025
HOSE:DCL Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 | 2016 - 2020 |
| Revenue | 1,306,797 | 1,143,946 | 1,015,686 | 703,634 | 671,246 | Upgrade
|
| Revenue Growth (YoY) | 14.24% | 12.63% | 44.35% | 4.83% | -10.74% | Upgrade
|
| Cost of Revenue | 1,102,093 | 934,032 | 733,585 | 493,482 | 483,609 | Upgrade
|
| Gross Profit | 204,704 | 209,914 | 282,100 | 210,152 | 187,637 | Upgrade
|
| Selling, General & Admin | 144,874 | 139,188 | 153,815 | 123,371 | 139,733 | Upgrade
|
| Operating Expenses | 144,874 | 139,188 | 153,815 | 123,371 | 139,733 | Upgrade
|
| Operating Income | 59,830 | 70,726 | 128,285 | 86,781 | 47,904 | Upgrade
|
| Interest Expense | -25,494 | -30,530 | -39,627 | -36,264 | -33,264 | Upgrade
|
| Interest & Investment Income | 34,279 | 39,667 | 52,712 | 51,929 | 71,400 | Upgrade
|
| Currency Exchange Gain (Loss) | 152.37 | -2,705 | 77.03 | -90.68 | 468.88 | Upgrade
|
| Other Non Operating Income (Expenses) | 9.56 | 953.02 | 94.19 | 6,058 | -564.86 | Upgrade
|
| EBT Excluding Unusual Items | 68,777 | 78,111 | 141,542 | 108,412 | 85,944 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 1,872 | - | Upgrade
|
| Pretax Income | 68,777 | 78,111 | 141,542 | 110,284 | 85,944 | Upgrade
|
| Income Tax Expense | 14,631 | 15,976 | 28,628 | 22,528 | 17,017 | Upgrade
|
| Earnings From Continuing Operations | 54,145 | 62,134 | 112,914 | 87,756 | 68,928 | Upgrade
|
| Minority Interest in Earnings | -574.4 | -416.96 | -1,273 | -1,796 | -2,537 | Upgrade
|
| Net Income | 53,571 | 61,717 | 111,641 | 85,961 | 66,391 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | 2,000 | 3,000 | 2,000 | 2,110 | Upgrade
|
| Net Income to Common | 53,571 | 59,717 | 108,641 | 83,961 | 64,281 | Upgrade
|
| Net Income Growth | -13.20% | -44.72% | 29.87% | 29.48% | -24.96% | Upgrade
|
| Shares Outstanding (Basic) | 73 | 73 | 70 | 57 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 73 | 73 | 70 | 57 | 57 | Upgrade
|
| Shares Change (YoY) | - | 4.11% | 22.02% | 1.17% | -24.64% | Upgrade
|
| EPS (Basic) | 733.44 | 817.59 | 1548.46 | 1460.20 | 1131.05 | Upgrade
|
| EPS (Diluted) | 733.00 | 817.59 | 1548.00 | 1460.00 | 1131.00 | Upgrade
|
| EPS Growth | -10.35% | -47.18% | 6.03% | 29.09% | -7.94% | Upgrade
|
| Free Cash Flow | -103,037 | -200,343 | -683,099 | -123,174 | -8,582 | Upgrade
|
| Free Cash Flow Per Share | -1410.67 | -2742.89 | -9736.25 | -2142.18 | -151.01 | Upgrade
|
| Gross Margin | 15.67% | 18.35% | 27.77% | 29.87% | 27.95% | Upgrade
|
| Operating Margin | 4.58% | 6.18% | 12.63% | 12.33% | 7.14% | Upgrade
|
| Profit Margin | 4.10% | 5.22% | 10.70% | 11.93% | 9.58% | Upgrade
|
| Free Cash Flow Margin | -7.89% | -17.51% | -67.25% | -17.51% | -1.28% | Upgrade
|
| EBITDA | 97,686 | 109,004 | 166,420 | 121,054 | 76,184 | Upgrade
|
| EBITDA Margin | 7.47% | 9.53% | 16.38% | 17.20% | 11.35% | Upgrade
|
| D&A For EBITDA | 37,856 | 38,278 | 38,135 | 34,273 | 28,280 | Upgrade
|
| EBIT | 59,830 | 70,726 | 128,285 | 86,781 | 47,904 | Upgrade
|
| EBIT Margin | 4.58% | 6.18% | 12.63% | 12.33% | 7.14% | Upgrade
|
| Effective Tax Rate | 21.27% | 20.45% | 20.23% | 20.43% | 19.80% | Upgrade
|
| Revenue as Reported | 1,143,946 | - | 1,015,686 | 703,634 | 671,246 | Upgrade
|
Updated Jan 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.